Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trialFlorence Ader, Raphaël Clère-Jehl, David Bougon et al.|The Lancet Infectious Diseases|2021Cited by 344
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trialsAlain Amstutz, Matthias Briel, Benjamin Speich et al.|The Lancet Respiratory Medicine|2023Cited by 124
Case-Control Study of Drug Monitoring of β-Lactams in Obese Critically Ill PatientsMaya Hites, Frédérique Jacobs, Fabio Silvio Taccone et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 117
Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Isabelle Delattre, Paul M. Tulkens, Fabio Taccone et al.|Expert Review of Anti-infective Therapy|2017Cited by 103
β-lactam antibiotic concentrations during continuous renal replacement therapyMarjorie Beumier, Fabio Silvio Taccone, Giuseppe Stefano Casu et al.|Critical Care|2014Cited by 92